SGRY (Surgery Partners Inc.) stock is in for a key growth catalyst

Surgery Partners Inc. (NASDAQ: SGRY) closed the day trading at $35.16 down -3.06% from the previous closing price of $36.27. In other words, the price has decreased by -$1.11 from its previous closing price. On the day, 652053 shares were traded. SGRY stock price reached its highest trading level at $35.86 during the session, while it also had its lowest trading level at $34.93.

Top 5 EV Tech Stocks to Buy for 2023

According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.

Click Here to Download the FREE Report.



For a better understanding of SGRY, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 18.15 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 66.71. For the most recent quarter (mrq), Quick Ratio is recorded 1.70 and its Current Ratio is at 1.80. In the meantime, Its Debt-to-Equity ratio is 1.32 whereas as Long-Term Debt/Eq ratio is at 1.29.

Upgrades & Downgrades

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 17 when Owens Bradley R. sold 7,191 shares for $36.31 per share. The transaction valued at 261,105 led to the insider holds 74,189 shares of the business.

Evans Jason Eric sold 7,674 shares of SGRY for $262,911 on Mar 31. The Chief Executive Officer now owns 426,790 shares after completing the transaction at $34.26 per share. On Mar 15, another insider, Evans Jason Eric, who serves as the Chief Executive Officer of the company, sold 99 shares for $30.10 each. As a result, the insider received 2,980 and left with 414,056 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SGRY now has a Market Capitalization of 4.98B and an Enterprise Value of 7.63B. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.71 while its Price-to-Book (P/B) ratio in mrq is 2.24. Its current Enterprise Value per Revenue stands at 2.92 whereas that against EBITDA is 18.50.

Stock Price History:

Over the past 52 weeks, SGRY has reached a high of $41.80, while it has fallen to a 52-week low of $20.46. The 50-Day Moving Average of the stock is 35.60, while the 200-Day Moving Average is calculated to be 30.92.

Shares Statistics:

Over the past 3-months, SGRY traded about 627.05K shares per day on average, while over the past 10 days, SGRY traded about 493.96k shares per day. A total of 125.21M shares are outstanding, with a floating share count of 53.58M. Insiders hold about 0.20% of the company’s shares, while institutions hold 83.00% stake in the company. Shares short for SGRY as of Apr 27, 2023 were 4.69M with a Short Ratio of 4.69M, compared to 5.04M on Mar 30, 2023. Therefore, it implies a Short% of Shares Outstanding of 3.71% and a Short% of Float of 9.65%.

Earnings Estimates

Current recommendations for the stock of the company come from 11 analysts. On average, analysts expect EPS of $0.08 for the current quarter, with a high estimate of $0.14 and a low estimate of $0.02, while EPS last year was -$0.03. The consensus estimate for the next quarter is $0.12, with high estimates of $0.22 and low estimates of $0.05.

Analysts are recommending an EPS of between $0.92 and $0.48 for the fiscal current year, implying an average EPS of $0.64. EPS for the following year is $0.83, with 11 analysts recommending between $1.28 and $0.64.

Revenue Estimates

9 analysts predict $670.06M in revenue for the current quarter. It ranges from a high estimate of $681.93M to a low estimate of $659.61M. As of the current estimate, Surgery Partners Inc.’s year-ago sales were $615.4M, an estimated increase of 8.90% from the year-ago figure. For the next quarter, 9 analysts are estimating revenue of $672.23M, an increase of 5.90% less than the figure of $8.90% in the same quarter last year. There is a high estimate of $683M for the next quarter, whereas the lowest estimate is $660.65M.

A total of 11 analysts have provided revenue estimates for SGRY’s current fiscal year. The highest revenue estimate was $2.86B, while the lowest revenue estimate was $2.75B, resulting in an average revenue estimate of $2.78B. In the same quarter a year ago, actual revenue was $2.54B, up 9.40% from the average estimate. Based on 11 analysts’ estimates, the company’s revenue will be $3.05B in the next fiscal year. The high estimate is $3.25B and the low estimate is $2.97B. The average revenue growth estimate for next year is up 9.70% from the average revenue estimate for this year.